Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

Advanced Drug Delivery Reviews

Volumn 58, Issue 5-6, 2006, Pages 640-656

  Presta, Leonard G ^a  

^a Schering Plough Biopharma ^*  (United States)

Author keywords

Effector function; Fc receptor; FcRn; Humanization

Indexed keywords

ANTIGENS; CELL CULTURE; IMMUNOLOGY; OPTIMIZATION; TOXICITY;

CYTOTOXICITY; EFFECTOR FUNCTION; FC RECEPTOR; FCRN; HUMANIZATION;

ANTIBODIES;

ABCIXIMAB; ALEMTUZUMAB; BASILIXIMAB; CD3 ANTIBODY; CD4 ANTIBODY; CD47 ANTIBODY; CETUXIMAB; COMPLEMENT COMPONENT C1Q; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC RECEPTOR; HER 2 ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; OKT 3; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS LIGAND RECEPTOR 2 ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BRONCHOSPASM; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG CLEARANCE; DRUG HALF LIFE; DYSPNEA; FEVER; GENE TARGETING; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; LUNG EDEMA; LYMPHOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPLEMENT C1Q; HUMANS; MICE; MICE, TRANSGENIC; PROTEIN ENGINEERING; SPECIES SPECIFICITY;

EID: 33747616656     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.01.026     Document Type: Review

References (165)

1. Pavlou A.K., and Belsey M.J. The therapeutic antibodies to market to 2008. Eur. J. Pharm. Biopharm. 59 (2005) 389-396
2. Lonberg N. Human antibodies from transgenic animals. Nat. Biotechnol. 23 (2005) 1117-1125
3. Hoogenboom H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23 (2005) 1105-1116
4. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
5. Carter P. Bispecific human IgG by design. J. Immunol. Methods 248 (2001) 7-15
6. Miller K., Meng G., Liu J., Hurst A., Hsei V., Wong W.-L., Ekert R., Lawrence D., Sherwood S., DeForge L., Gaudreault J., Keller G., Sliwkowski M., Ashkenazi A., and Presta L. Design, construction, and in vitro analyses of multivalent antibodies. J. Immunol. 170 (2003) 4854-4861
7. Wu A., and Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23 (2005) 1137-1146
8. Dela Cruz J.S., Huang T.H., Penichet M.L., and Morrison S.L. Antibody-cytokine fusion proteins: innovative weapon in the war against cancer. Clin. Exp. Med. 4 (2004) 57-64
9. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
10. Mirick G.R., Bradt B.M., DeNardo S.J., and DeNardo G.L. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. J. Nucl. Med. Mol. Imaging 48 (2004) 251-257
11. Morrison S.L., Johnson M.J., Herzenberg L.A., and Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 685106855
12. Hwang W.Y.K., and Foote J. Immunogenicity of engineered antibodies. Methods 36 (2005) 3-10
13. Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin. Arthritis Rheum. 34 Suppl. 1 (2005) 19-22
14. Chinn P., Braslawsky G., White C., and Hanna N. Antibody therapy of non-Hodgkin's B-cell lymphoma. Cancer Immunol. Immunother. 52 (2003) 257-280
15. Wagner C.L., Schantz A., Barnathan E., Olson A., Mascelli M.A., Ford J., Damaraju L., Schaible T., Maini R.N., and Tcheng J.E. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. In: Brown F., and Mire-Sluis A.R. (Eds). Dev. Biol. vol. 112 (2003), Karger, Basel 37-53
16. Kabat E.A., Wu T.T., Perry H.M., Gottesman K.S., and Froeller C. Sequences of Proteins of Immunological Interest. 5th ed. vol. 1 (1991) xvi NIH Publ. No. 91-3242
17. Chothia C., and Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196 (1987) 901-917
18. Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986) 522-525
19. Reichmann L., Clark M., Waldmann H., and Winter G. Reshaping human antibodies for therapy. Nature 332 (1988) 323-327
20. Queen C., Schneider W.P., Selick H.E., Payne P.W., Landolfi N.F., Duncan J.F., Avdalovic N.M., Levitt M., Junghans R.P., and Waldmann T.A. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 10029-10033
21. Carter P.C., Presta L.G., Gorman C.M., Ridgway J.B.B., Henner D., Wong W.-L.T., Rowland A.M., Kotts C., Carver M.E., and Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4285-4289
22. Tsurushita N., Park M., Pakabunto K., Ong K., Avdalovic A., Fu H., Jia A., Vasquez M., and Kumar S. Humanization of a chicken anti-IL-12 monoclonal antibody. J. Immunol. Methods 295 (2004) 9-19
23. Padlan E.A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28 (1991) 489-498
24. Zhang W., Feng J., Li Y., Guo N., and Shen B. Humanization of an anti-human TNF-α antibody by variable region resurfacing with the aid of molecular modeling. Mol. Immunol. 42 (2005) 1445-1451
25. Kashmiri S.V.S., De Pascalis R., Gonzales N.R., and Schlom J. SDR grafting - a new approach to antibody humanization. Methods 36 (2005) 25-34
26. Hwang W.Y.K., Almagro J.C., Buss T.N., Tan P., and Foote J. Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods 36 (2005) 35-42
27. Tan P., Mitchell D.A., Buss T.N., Holmes M.A., Anasetti C., and Foote J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol. 169 (2002) 1119-1125
28. Dall'Acqua W.F., Damschroder M.M., Zhang J., Woods R.M., Widjaja L., Yu J., and Wu H. Antibody humanization by framework shuffling. Methods 36 (2005) 43-60
29. Roque-Navarro L., Mateo C., Lombardero J., Mustelier G., Fernandez A., Sosa K., Morrison S.L., and Perez R. Humanization of predicted T-cell epitopes reduces the immunogenicitty of chimeric antibodies: new evidence supporting a simple method. Hybrid. Hybridomics 22 (2003) 245-257
30. Bander N.H., Milowsky M.J., Nanus D.M., Kostakoglu L., Vallabhajosula S., and Goldsmith S.J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 23 (2005) 4591-4601
31. Gillies S.D., Lan Y., Williams S., Carr F., Forman S., Raubitschek A., and Lo K.-M. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105 (2005) 3972-3976
32. Peng W., Zhang X., Mohamed N., Inghirami G., Takeshita K., Pecora A., Nardone L.L., Pincus S.E., Casey L.S., and Spitalny G.L. A deimmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunol. Immunother. 54 (2005) 1172-1179
33. Henry M.D., Wen S., Silva M.D., Chandra S., Milton M., and Worland P.J. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64 (2004) 7995-8001
34. Hansson L., Rabbani H., Fagerberg J., Österborg A., and Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 101 (2003) 4930-4936
35. Bradbury A.R.M., and Marks J.D. Antibodies from phage antibody libraries. J. Immunol. Methods 290 (2004) 29-49
36. Son J.H., Lee U.H., Lee J.J., Kwon B., Kwon B.S., and Park J.W. Humanization of agonistic anti-human 4-1BB monoclonal antibody using phage-displayed combinatorial library. J. Immunol. Methods 286 (2004) 187-201
37. Steinberger P., Sutton J.K., Rader C., Elia M., and Barbas III C.F. Generation and characterization of a recombinant human CCR5-specific antibody. J. Biol. Chem. 275 (2000) 36073-36078
38. Baca M., Presta L.G., O'Connor S.J., and Wells J.A. Antibody humanization using monovalent phage display. J. Biol. Chem. 279 (1997) 10678-10684
39. Rosok M.J., Yelton D.E., Harris L.J., Bajorath J., Hellström K.-E., Hellström I., Cruz G.A., Kristensson K., Liu H., Huse W.D., and Glaser S.M. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab. J. Biol. Chem. 271 (1996) 22611-22618
40. Neve R.M., Nielsen U.B., Kirpotin D.B., Poul M.-A., Marks J.D., and Benz C.C. Biological effects of anti-Erb2 single chain antibodies selected for internalizing function. Biochem. Biophys. Res. Commun. 280 (2001) 274-279
41. Heitner T., Moor A., Garrison J.L., Marks C., Hasan T., and Marks J.D. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J. Immunol. Methods 248 (2001) 17-30
42. Ewert S., Honegger A., and Plückthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 34 (2004) 184-199
43. Wörn A., and Plückthun A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305 (2001) 989-1010
44. Visintin M., Settanni G., Maritan A., Grazios S., Marks J.D., and Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J. Mol. Biol. 317 (2002) 73-83
45. Marasco W.A. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology 1 (1995) 1-19
46. Desiderio A., Franconi R., Lopez M., Villani M.E., Viti F., Chiaraluce R., Consalvi V., Neri D., and Benevenuto E. A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold. J. Mol. Biol. 310 (2001) 603-615
47. Colby D.W., Chu Y., Cassady J.P., Duennwald M., Zazulak H., Webster J.M., Messer A., Lindquist S., Ingram V.M., and Wittrup K.D. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17616-17621
48. Roberts S., Cheetham J.C., and Rees A.R. Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering. Nature 328 (1987) 731-734
49. Ho M., Kreitman R.J., Onda M., and Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J. Biol. Chem. 280 (2005) 607-617
50. Rajpal A., Beyaz N., Haber L., Cappuccilli G., Yee H., Bhatt R.R., Takeuchi T., Lerner R.A., and Crea R. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8466-8471
51. Lipovsek D., and Plückthun A. In-vitro protein evolution by ribosome display and mRNA display. J. Immunol. Methods 290 (2004) 51-67
52. Graff C.P., Chester K., Begent R., and Wittrup K.D. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 °C. Protein Eng. Des. Sel. 17 (2004) 293-304
53. Schlapschy M., Gruber H., Gresch O., Shäfer C., Renner C., Pfreundschuh M., and Skerra A. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach. Protein Eng. Des. Sel. 17 (2004) 847-860
54. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., MArks J.D., and Weiner L.M. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61 (2001) 4750-4755
55. Nielsen U.B., Adams G.P., Weiner L.M., and Marks J.D. Targeting of bivalent anti-Erb2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 60 (2000) 6434-6440
56. Hexham J.M., Dudas D., Hugo R., Thompson J., King V., Dowling C., Neville D.M., Digan M.E., and Lake P. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins. Mol. Immunol. 38 (2001) 397-408
57. Agus D.B., Gordon M.S., Taylor C., Natale R.B., Karlan B., Mendelson D.S., Press M.F., Allison D.E., Sliwkowski M.X., Lieberman G., Kelsey S.M., and Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 23 (2005) 2534-2543
58. Wang Y., Fei D., Vanderlaan M., and Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7 (2004) 335-345
59. Chan L.A., Phillips M.L., Wims L.A., Trinh K.R., Denham J., and Morrison S.L. Variable region domain exchange in human IgGs promotes antibody complex formation with accompanying structural changes and altered effector functions. Mol. Immunol. 41 (2004) 527-538
60. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol. Immunol. 41 (2004) 1089-1098
61. Gaboriaud C., Thielens N.M., Gregory L.A., Rossi V., Fontecilla-Camps J.C., and Arlaud G.J. Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol. 25 (2004) 368-373
62. Brekke O.H., Michaelsen T.E., and Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge?. Immunol. Today 16 (1995) 85-90
63. Duncan A.R., and Winter G. The binding site for C1q on IgG. Nature 332 (1988) 738-740
64. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., Meng Y.G., and Mulkerrin M.G. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164 (2000) 4178-4184
65. Thommesen J.E., Michaelsen T.E., Løset G.A., Sandlie I., and Brekke O.H. Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation. Mol. Immunol. 37 (2000) 995-1004
66. Krapp S., Mimura Y., Jefferis R., Huber R., and Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325 (2003) 979-989
67. Boyd P.N., Lines A.C., and Patel A.K. The effect of the removal of sialic acid, galactose, and total carbohydrate on the functional activity of CAMPATH-1H. Mol. Immunol. 32 (1995) 1311-1318
68. Jassal R., Jenkins N., Charlwood J., Camilleri P., Jefferis R., and Lund J. Sialylation of human IgG Fc carbohydrate by transfected rat α-2,6-sialyltransferase. Biochem. Biophys. Res. Commun. 286 (2001) 243-249
69. Wright A., and Morrison S.L. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J. Immunol. 160 (1998) 3393-3402
70. Malhotra R., Wormald M.R., Rudd P.M., Fischer P.B., Dwek R.A., and Sim R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1 (1995) 237-243
71. Michaelsen T.E., Garred P., and Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol. 21 (1991) 11-16
72. Lucisano Valim Y.M., and Lachmann P.J. The effect of antibody isotype and antigenic density on the complement-fixing activity of immune complexes: a systematic study using chimeric anti-NIP antibodies with human Fc regions. Clin. Exp. Immunol. 84 (1991) 1-8
73. Idusogie E.E., Wong P.Y., Presta L.G., Gazzano-Santoro H., Totpal K., Ultsch M., and Mulkerrin M.G. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166 (2001) 2571-2575
74. Cohen-Solal J.F., Cassard L., Fridman W.H., and Sautes-Fridman C. Fc gamma receptors. Immunol. Lett. 92 (2004) 199-205
75. van Sorge N.M., van der Pol W.L., and van de Winkel J.G. FcγR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61 (2003) 189-202
76. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., and Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIA gene. Blood 99 (2002) 754-758
77. Kono H., Kyogoku C., Suzuki T., Tsuchiya N., Honda H., Yamamoto K., Tokunaga K., and Honda Z. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 14 (2005) 2881-2892
78. Blank M.C., Stefanescu R.N., Masuda E., Marti F., King P.D., Redecha P.B., Wurzburger R.J., Petereson M.G.E., Tanaka S., and Pricop L. Decreased transcription of the human FCGR2B gene mediated by the - 343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum. Genet. 117 (2005) 220-227
79. Bruin M., Bierings M., Uiterwaal C., Revesz T., Bode L., Wiesman M.-E., Kuijpers T., Tamminga R., and de Haas M. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br. J. Haematol. 127 (2004) 561-567
80. Karassa F.B., Trikalinos T.A., and Ioannidis J.P.A. The role of FcγRIIA and IIIA polymorphisms in autoimmune diseases. Biomed. Pharmacother. 58 (2004) 286-291
81. Kastbom A., Ahmadi A., Söderkvist P., and Skogh T. The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology 44 (2005) 1294-1298
82. van Sorge N.M., van der Pol W.-L., Jansen M.D., Geleijns K.P.W., Kalmijn S., Hughes R.A.C., Rees J.H., Pritchard J., Vedeler C.A., Myhr K.-M., Shaw C., van Schaik I.N., Wokke J.H.J., van Doorn P.A., Jacobs B.C., van de Winkel J.G.J., and van den Berg L.H. Severity of Guillain-Barre syndrome is associated with Fcγ receptor III polymorphisms. J. Neuroimmunol. 162 (2005) 157-164
83. Brouwer K.C., Lal A.A., Mirel L.B., Otieno J., Ayisi J., van Eijk A.N., Lal R.B., Steketee R., Nahlen B.L., and Shi Y.P. Polymorphism of Fc receptor IIa for immunoglobulin G is associated with placental malaria in HIV-1-positive women in western Africa. J. Infect. Dis. 190 (2004) 1192-1198
84. Gruel Y., Pouplard C., Lasne D., Magdelaine-Beuzelin C., Charroing C., and Watier H. The homozygous FcγRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 104 (2004) 2791-2793
85. Gavasso S., Nygård O., Pedersen E.R., Aarseth J.H., Bleie Ø., Myhr K.-M., and Vedeler C.A. Fcγ receptor IIIa polymorphism as a risk factor for coronary artery disease. Atherosclerosis 180 (2005) 277-282
86. van der Meer I.M., Witteman J.C.M., Hofman A., Kluft C., and de Maat M.P.M. Genetic variation in Fcγ receptor IIa protects against advanced peripheral atherosclerosis. Thromb. Haemost. 92 (2004) 1273-1276
87. Pawlik A., Florczak M., Bak L., Dabrowska-Zamojcin E., Rozanski J., Domanski L., and Gawronska-Szklarz B. The FcγRIIa polymorphism in patients with chronic kidney graft rejection. Transplant. Proc. 36 (2004) 1311-1313
88. van der Straaten H.M., Fijnheer R., Nieuwenhuis H.K., van de Winkel J.G.J., and Verdonck L.F. The FcγRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 11 (2005) 206-212
89. Carton G., Watier H., Golay J., and Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642
90. Treon S.P., Hansen M., Branagan A.R., Verselis S., Emmanouilides C., Kimby E., Frankel S.R., Touroutoglou N., Turnbull B., Anderson K.C., Maloney D.G., and Fox E.A. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J. Clin. Oncol. 23 (2005) 474-481
91. Ghielmini M., Rufibach K., Salles G., Leoncini-Franscini L., Leger-Falandry C., Cogliatti S., Fey M., Martinelli G., Stahel R., Lohri A., Ketterer N., Wernli M., Cerny T., and Schmitz S.-F.H. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 16 (2005) 1675-1682
92. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., and Looney R.J. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48 (2003) 455-459
93. Weng W.-K., Czerwinski D., Timmerman J., Hsu F.J., and Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22 (2004) 4665-4672
94. Lin T.S., Flinn I.W., Modali R., Lehman T.A., Webb J., Waymer S., Moran M.E., Lucas M.S., Farag S.S., and Byrd J.C. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105 (2005) 289-291
95. Xu D., Alegre M.L., Varga S.S., Rothermel A.L., Collins M., Pulito V.L., Hanna L.S., Dolan K.P., Parren P.W., Bluestone J.A., Jolliffe L.K., and Zivin R.A. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 200 (2000) 16-26
96. Carpenter P.A., Pavlovic S., Tso J.Y., Press O.W., Gooley T., Yu X.Z., and Anasetti C. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 165 (2000) 6205-6213
97. Bolt S., Routledge E., Lloyd I., Chatenoud L., Pope H., Gorman S.D., Clark M., and Waldmann H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23 (1993) 403-411
98. Newman R., Hariharan K., Reff M., Anderson D.R., Braslawsky G., Santoro D., Hanna N., Bugelski P.J., Brigham-Burke M., Crysler C., Gagnon R.C., Dal Monte P., Doyle M.L., Hensley P.C., Reddy M.P., Sweet R.W., and Truneh A. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4+ T cells in chimpanzees. Clin. Immunol. 98 (2001) 164-174
99. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., and Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763-1769
100. Carpenter P.A., Lowder J., Johnston L., Frangoul H., Khoury H., Parker P., Jerome K.R., McCune J.S., Storer B., Martin P., Appelbaum F., Abonour R., Westervelt P., and Anasetti C. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant. 11 (2005) 465-471
101. Dillman R.O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 18 (1999) 465-471
102. Plosker G.L., and Figgitt D.P. Rituximab. A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 63 (2003) 803-843
103. Leonard J.P., Coleman M., Ketas J., Ashe M., Fiore J.M., Furman R.R., Niesvizky R., Shore T., Chadburn A., Horne H., Kovacs J., Ding C.L., Wegener W.A., Horak I.D., and Goldenberg D.M. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 23 (2005) 5044-5051
104. Feldman E.J., brandwein J., Stone R., Kalaycio M., Moore J., O'Connor J., Wedel N., Roboz G.J., Miller C., Chopra R., Jurcic J.C., Brown R., Ehmann W.C., Schulman P., Frankel S.R., De Angelo D., and Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 23 (2005) 4110-4116
105. Frampton J.E., and Wagstaff A.J. Alemtuzumab. Drugs 63 (2003) 1229-1243
106. Armour K.L., Clark M.R., Hadley A.G., and Williamson L.M. Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities. Eur. J. Immunol. 29 (1999) 2613-2624
107. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding to the Fcγ. J. Biol. Chem. 276 (2001) 6591-6604
108. Hsu D.-H., Shi J.D., Homola M., Rowell T.J., Moran J., Levitt D., Druilhet B., Chinn J., Bullock C., and Klingbeil C. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation 68 (1999) 545-554
109. Reddy M.P., Kinney C.A.S., Chaiken M.A., Payne A., Fishman-Lobell J., Tsui P., Dal Monte P.R., Doyle M.L., Brigham-Burke M.R., Anderson D., Reff M., Newman R., Hanna N., Sweet R.W., and Truneh A. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 164 (2000) 1925-1933
110. Greenwood J., Clark M., and Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur. J. Immunol. 23 (1993) 1098-1104
111. Isaacs J.D., Wing M.G., Greenwood J.D., Hazleman B.L., Hale G., and Waldmann H. A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin. Exp. Immunol. 106 (1996) 427-433
112. Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Roberts G., Pedley B., and Adair J.R. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30 (1993) 105-108
113. Deng L., Wylie D., Tsao Y.S., Larkin B., Voloch M., and Ling W.L. Detection and quantification of the human IgG4 half-molecule, HL, from unpurified cell-culture supernatants. Biotechnol. Appl. Biochem. 40 (2004) 261-269
114. Lund J., Takahashi N., Pound J.D., Goodall M., Nakagawa H., and Jefferis R. Oligosaccharide-protein interactions in IgG can modulate recognition by fc gamma receptors. FASEB J. 9 (1995) 115-119
115. Morgan A., Jones N.D., Nesbitt A.M., Chaplin L., Bodmer M.W., and Emtage J.S. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA DR is necessary for C1q, FcγRI and FcγRIII binding. Immunology 86 (1995) 318-324
116. Leatherbarrow R.J., Rademacher T.W., Dwek R.A., Woof J.M., Clark A., Burton D.R., Richardson N., and Feinstein A. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol. Immunol. 22 (1985) 407-415
117. Tao M.-H., and Morrison S.L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143 (1989) 2595-2601
118. Ferrant J.L., Benjamin C.D., Cutler A.H., Kalled S.L., Hsu Y.-M., Garber E.A., Hess D.M., Shapiro R.I., Kenyon N.S., Harlan D.M., Kirk A.D., Burkly L.C., and Taylor F.R. The contribution of Fc effector function mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Int. Immunol. 16 (2004) 1583-1594
119. Rodriguez M., Ramirez N.I., Ayala M., Freyre F., Pererz L., Triguero A., Mateo C., Selman-Housein G., Gavilondo J.V., and Pujol M. Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor. Biotechnol. Bioeng. 89 (2005) 188-194
120. Ludwig D.L., Witte L., Hicklin D.J., Prewett M., Bassi R., Burtrum D., Pereira D.S., Jimenez X., Fox F., Saxena B., Zhou Q., Ma Y., Kang X., Patel D., Barry M., Kussie P., Zhu Z., Russell D.A., Petersen W.L., Jury T.P., Gaitan-Gaitan F., Moran D.L., Delannay X., Storrs B.S., Tou J., Zupee M.E., Gustafson K.S., McIntyre J., Tarnowski S.J., and Bohlen P. Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed. Hum. Antib. 13 (2004) 81-90
121. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J.-M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.-F., Pipeleers D., and Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352 (2005) 2598-2608
122. Motoki K., Mori E., Matsumoto A., Thomas M., Tomura T., Humphreys R., Albert V., Muto M., Yoshida H., Aoki M., Tamada T., Kuroki R., Yoshida H., Ishida I., Wane C.F., and Kataoka S. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin. Cancer Res. 11 (2005) 3126-3135
123. Kikuchi Y., Uno S., Kinoshita Y., Yoshimura Y., Iida S.-I., Wakahara Y., Tsuchiya M., Yamada-Okabe H., and Fukushima N. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk. Res. 29 (2005) 445-450
124. Stein R., Qu Z., Cardillo T.M., Chen S., Rosario A., Horak I.D., Hansen H.J., and Goldenberg D.M. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104 (2004) 3705-3711
125. Shan D., Ledbetter J.A., and Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91 (1998) 1644-1652
126. Flieger D., Renoth S., Beier I., Sauerbruch T., and Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell. Immunol. 204 (2000) 55-63
127. Ghetie M.-A., Bright H., and Vitetta E.S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97 (2001) 1392-1398
128. Anderson D.R., Grillo-Lopez A., Varns C., Chambers K.S., and Hanna N. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25 (1997) 705-708
129. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6 (2000) 443-446
130. Jazirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
131. Cragg M.S., Morgan S.M., Chan H.T.C., Morgan B.P., Filatov A.V., Johnson P.W.M., French R.R., and Glennie M.J. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101 (2003) 1045-1052
132. Golay J., Zaffroni L., Vaccari T., Lazzari M., Borleri G.-M., Bernasconi S., Tedesco F., Rambaldi A., and Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody Rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 (2000) 3900-3908
133. Weng W.-K., and Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98 (2001) 1352-1357
134. Stein R., Qu Z., Chen S., Rosario A., Shi V., Hayes M., Horak I.D., Hansen H.J., and Goldenberg D.M. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res. 10 (2004) 2868-2878
135. Blumenthal R.D., Osorio L., Hayes M.K., Horak I.D., Hansen H.J., and Goldenberg D.M. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol. Immunother. 54 (2005) 315-327
136. Tai Y.-T., Li X., Tong X., Santos D., Otsuki T., Catley L., Tournilhac O., Podar K., Hideshima T., Schlossman R., Richardson P., Munshi N.C., Luqman M., and Anderson K.C. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 65 (2005) 5898-5906
137. Zeng Y., Fest S., Kunert R., Katinger H., Pistoia V., Michon J., Lewis G., Ladenstein R., and Lode H.N. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol. Immunol. 42 (2005) 1311-1319
138. Sampson J.H., Crotty L.E., Lee S., Archer G.E., Ashley D.M., Wikstrand C.J., Hale L.P., Small C., Dranoff G., Friedman A.H., Friedman H.S., and Bigner D.D. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7503-7508
139. Hombach A., Heuser C., and Abken H. Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int. J. Cancer 115 (2005) 241-247
140. Scallon B., Cai A., Radewonuk J., and Naso M. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency. Mol. Immunol. 41 (2004) 73-80
141. Raju T.S., Briggs J.B., Borge S.M., and Jones A.J. Species-specific variation in glycosylation of IgG: evidence for the species-specific
142. Gala F.A., and Morrison S.L. V region carbohydrate and antibody expression. J. Immunol. 172 (2004) 5489-5494
143. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21 (2005) 11-16
144. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H.A., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002) 26733-26740
145. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., and Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 276 (2003) 3466-3473
146. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., Wakitani M., Niwa R., Sakurada M., Uchida K., Shitara K., and Satoh M. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 67 (2004) 614-622
147. Niwa R., Hatanaka S., Shoji-Hosaka E., Sakurada M., Kobayashi Y., Uchara A., Yokoi H., Nakamura K., and Shitara K. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin. Cancer Res. 10 (2004) 6235-6248
148. Schuster M., Umana P., Ferrara C., Brünker P., Gerdes C., Waxenecker G., Wiederkum S., Schwager C., Loibner H., Himmler G., and Mudde G.C. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 65 (2005) 7934-7941
149. Niwa R., Sakurada M., Kobayashi Y., Uchara A., Matsushima K., Ueda R., Nakamura K., and Shitara K. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin. Cancer Res. 11 (2003) 2327-2336
150. Niwa R., Shoji-Hosaka E., Sakurada M., Shinkawa T., Uchida K., Nakamura K., Matsushima K., Ueda R., Hanai M., and Shitara K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64 (2004) 2127-2133
151. Wildt S., and Gerngross U. The humanization of N-glycosylation pathways in yeast. Nat. Rev., Microbiol. 3 (2005) 119-128
152. Chappel M.S., Isenman D.E., Oomen R., Xu Y.Y., and Klein M.H. Identification of a secondary FcgRI binding site within a genetically engineered human IgG antibody. J. Biol. Chem. 268 (1993) 25124-25131
153. G.A. Lazar, A.J. Chirino, W. Dang, J.R. Desjarlais, S.K. Doberstein, R.J. Hayes, S.B. Karki, O. Vafa, Optimized Fc variants and methods for their generation, U.S. Patent Application Publ. 2004/0132101 A1, July 8, 2004.
154. Brambell F.W., Hemmings W.A., and Morris I.G. A theoretical model of gamma-globulin catabolism. Nature 203 (1964) 1352-1354
155. Lencer W.I., and Blumberg R.S. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 15 (2005) 5-9
156. Martin W.L., West Jr. A.P., Gan L., and Bjorkman P.J. Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 7 (2001) 867-877
157. Stirling C.M.A., Charleston B., Takamatsu H., Claypool S., Lencer W., Blumberg R.S., and Wileman T.E. Characterization of the porcine neonatal Fc receptor - potential use for trans-epithelial protein delivery. Immunology 114 (2005) 533-542
158. Getman K.E., and Balthasar J.P. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J. Pharm. Sci. 94 (2005) 718-729
159. Medesan C., Matesoi D., Radu C., Ghetie V., and Ward E.S. Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J. Immunol. 158 (1997) 2211-2217
160. Ghetie V., Popov S., Borvak J., Radu C., Matesoi D., Ober R.J., and Ward E.S. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15 (1997) 637-640
161. Dall'Acqua W.F., Woods R.M., Ward E.S., Palaszynski S.R., Patel N.K., Brewah Y.A., Wu H., Kiener P.A., and Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169 (2002) 5171-5180
162. Vaccaro C., Zhou J., Ober R.J., and Ward E.S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23 (2005) 1283-1288
163. Hinton P.R., Johlfs M.G., Xiong J.M., Hanestad K., Ong K.C., Bullock C., Keller S., Tang M.T., Tso J.Y., Vasquez M., and Tsurushita N. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279 (2004) 6213-6216
164. Pop L.M., Liu X., Ghetie V., and Vitetta E.S. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutatioins which alter their serum half-life. Int. Immunol. 5 (2005) 1279-1290
165. Kenanova V., Olafsen T., Crow D.M., Sundaresan G., Subbarayan M., Carter N.H., Ikle D.N., Yazaki P.J., Chatziioannou A.F., Gambhir S.S., Williams L.E., Shively J.E., Colcher D., Raubitschek A.A., and Wu A.M. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 65 (2005) 622-631